Article
AI News

Isomorphic Labs raises $5 billion to push AI drugs toward trials

The Google DeepMind spinout's Series C, led by Greenoaks and Sequoia Capital, arrives six months after a $2.1 billion Series B.

by TechDefused · Edited by IL
The image depicts a laboratory setting focused on genomic analysis, featuring a digital screen displaying DNA sequencing data and graphical representations. A 3D model of a DNA double helix is prominently displayed alongside lab equipment and vials. aiImage created using AI — Chatgpt

Isomorphic Labs raises $5 billion to test whether AI can actually make drugs

The DeepMind spinout's record funding round is meant to get its AI-designed drugs into human trials

Isomorphic Labs has raised more money in six months than most biotech companies raise in their lifetimes.

The London-based AI drug-discovery company, spun out of Google DeepMind, has closed a $5 billion Series C round led by Greenoaks and Sequoia Capital.

Andreessen Horowitz and Alphabet, Isomorphic's parent company, also took part.

It is biotech's biggest venture round on record.

A rapid build-up

The raise comes just six months after a $2.1 billion Series B led by Thrive Capital in May.

That came after a $600 million first external round in 2025. Taken together, Isomorphic has raised $7.7 billion in less than two years.

From models to medicine

The money will fund IsoDDE, the company's AI drug-design engine, along with its own drug programmes and the infrastructure needed to take candidates into human clinical trials.

That last step is the real test.

AI has become good at predicting how molecules behave, but no company has yet shown that it can reliably turn those predictions into approved medicines.

Demis Hassabis, who founded Isomorphic in 2021, said in January that he expected its first clinical trials by the end of 2026.

That leaves about six weeks.

Built on AlphaFold

Isomorphic now has more than 200 employees and builds on DeepMind's AlphaFold research, which predicts the 3D shapes of proteins.

AlphaFold 3, developed with Google DeepMind and published in May 2024, extended that work to how proteins interact with other molecules, including potential drugs.

The company already works with Eli Lilly and Novartis, as well as Johnson & Johnson.

The Lilly and Novartis deals, announced in 2024, were worth about $3 billion combined including milestone payments.

Read more

by TechDefused